High rate of extra-haematological toxicity compromises dose-dense sequential adjuvant chemotherapy for breast cancer

6Citations
Citations of this article
33Readers
Mendeley users who have this article in their library.

Abstract

Background: A dose-dense strategy has been considered to improve results of adjuvant chemotherapy for breast cancer. This randomised phase II trial investigated the feasibility of this approach with sequential anthracyclines and taxanes-based chemotherapy. Methods: Patients with high-risk node-positive breast cancer were treated with three cycles of fluorouracil 500 mg m -2, epirubicin 100 mg m -2, cyclophosphamide 500 mg m -2 (FEC 100) followed by three cycles of docetaxel 100 mg m -2 delivered at 2-weekly intervals supported by primary prophylaxis with filgrastim. All patients were randomised to either uninterrupted treatment (arm A) or to have a 2-week additional period of rest between the FEC and docetaxel (arm B). The primary endpoint was the rate of success of chemotherapy delivery. Using a two-stage Fleming design, 120 patients were required with one interim analysis. Results: In March 2005, enrolment was stopped into arm A after the observation of severe skin toxicities. Following the planned interim analysis, the study was closed because of the high rate of grade 3/4 skin toxicities in both arms (arm A: 32.4% and arm B: 18.9%). Conclusion: Sequential dose-dense FEC 100 followed by docetaxel 100 mg m -2 is not feasible. Feasibility still depends largely on several factors including the choice of drugs, dosage and sequence of administration. © 2011 Cancer Research UK All rights reserved.

References Powered by Scopus

Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: First report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741

1458Citations
N/AReaders
Get full text

Thresholds for therapies: Highlights of the St Gallen international expert consensus on the primary therapy of early breast cancer 2009

1236Citations
N/AReaders
Get full text

The effect on tumor response of adding sequential preoperative docetaxel to preoperative doxorubicin and cyclophosphamide: Preliminary results from National Surgical Adjuvant Breast and Bowel Project Protocol B-27

1024Citations
N/AReaders
Get full text

Cited by Powered by Scopus

Loco-regional cancer drug therapy: Present approaches and rapidly reversible hydrophobization (RRH) of therapeutic agents as the future direction

30Citations
N/AReaders
Get full text

At cancer diagnosis: A 'window of opportunity' for behavioural change towards physical activity. A randomised feasibility study in patients with colon and breast cancer

27Citations
N/AReaders
Get full text

Dose-dense chemotherapy versus conventional chemotherapy for early breast cancer: A systematic review with meta-analysis

21Citations
N/AReaders
Get full text

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Cite

CITATION STYLE

APA

Brain, E., Levy, C., Serin, D., Roché, H., Spielmann, M., Delva, R., … Fumoleau, P. (2011). High rate of extra-haematological toxicity compromises dose-dense sequential adjuvant chemotherapy for breast cancer. British Journal of Cancer, 105(10), 1480–1486. https://doi.org/10.1038/bjc.2011.414

Readers' Seniority

Tooltip

PhD / Post grad / Masters / Doc 11

58%

Researcher 6

32%

Professor / Associate Prof. 2

11%

Readers' Discipline

Tooltip

Medicine and Dentistry 15

65%

Agricultural and Biological Sciences 4

17%

Nursing and Health Professions 2

9%

Psychology 2

9%

Save time finding and organizing research with Mendeley

Sign up for free